Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo

International Journal of Cancer

Volumn 122, Issue 12, 2008, Pages 2858-2863

  Dai, Yun ^a,b   Qiao, Liang ^b   Kwok, Wah Chan ^b   Zou, Bing ^b   Ma, Juan ^b   Lan, Hui Y ^b   Gu, Qing ^b   Li, Zesong ^b   Wang, Yan ^a   Wong, Benny L W ^b   Wong, Benjamin C Y ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colon cancer; in vivo; PPAR ; Rosiglitazone; Therapy

Indexed keywords

KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ROSIGLITAZONE; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; HUMANS; IN SITU NICK-END LABELING; PPAR GAMMA; THIAZOLIDINEDIONES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 43049093730     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23443     Document Type: Article

References (36)

1. Panigrahy D, Shen LQ, Kieran MW, Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Invest Drugs 2003;12:1925-37.
2. Koeffler HP. Peroxisome proliferator-activated receptor-γ and cancers. Clin Cancer Res 2003;9:1-9.
3. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-52.
4. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 1999;3:799-804.
5. Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998;115:1049-55.
6. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor-γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999;90:75-80.
7. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002;50:658-64.
8. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC, Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-γ is associated with Bcl-2 and NF-κB in human colon cancer. Life Sci 2002;70:2631-46.
9. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Miwa K. Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 2004;25:631-9.
10. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053-7.
11. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998;4:1058-61.
12. Yang K, Fan KH, Lamprecht SA, Edelmann W, Kopelovich L, Kucherlapati R, Lipkin M. Peroxisome proliferator-activated receptor-γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc(1638 N/+) Mlh1(+/-) double mutant mice. Int J Cancer 2005;116:495-9.
13. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen XQ, Vanbogelen R, Leff T. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 2000;49:539-47.
14. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M, Mannelli M. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005;90:1332-9.
15. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U. Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 2005;213:157-8.
16. Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor-γ. World J Gastroenterol 2007;13:1534-40.
17. Liu Y, Meng Y, Liu H, Li J, Fu J, Liu Y, Chen X. Growth inhibition and differentiation induced by peroxisome proliferator activated receptor γ ligand rosiglitazone in human melanoma cell line a375. Med Oncol 2006;23:393-402.
18. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor-γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7.
19. Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T, Sano H. Expression of peroxisome proliferator-activated receptor-γ in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001;287:727-32.
20. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23:100-8.
21. Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-activated receptor-γ inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J Dig Dis 2007;8:82-8.
22. Yang C, Jo SH, Csernus B, Hyjek E, Liu Y, Chadburn A, Wang YL. Activation of peroxisome proliferator-activated receptor-γ contributes to the survival of T lymphoma cells by affecting cellular metabolism. Am J Pathol 2007;170:722-32.
23. Talbert DR, Allred CD, Zaytseva YY, Kilgore MW. Transactivation of ERα by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat 2008;108:23-33.
24. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ. Cancer Res 2005;65:1561-9.
25. Lei P, Abdelrahim M, Safe S. 1,1-Bis(3′-indolyl)-1-(p- substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. Mol Cancer Ther 2006;5:2324-36.
26. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004;64:3006-8.
27. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Rocke C, Farrell G. Constitutive activation of NF-κB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther 2006;17:280-90.
28. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H. Peroxisome proliferator-activated receptor-γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-7.
29. Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, Farrar WB, Walker MJ, Povoski SP, Suster S, Eng C. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 2007;13:246-52.
30. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, Greenspan FS, Lindsay S, Duh QY, Morita EA. Phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-6.
31. Cerbone A, Toaldo C, Laurora S, Briatore F, Pizzimenti S, Dianzani MU, Ferretti C, Barrera G. 4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. Free Radic Biol Med 2007;42:1661-70.
32. Maehama T. PTEN: its deregulation and tumorigenesis. Biol Pharm Bull 2007;30:1624-7.
33. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007;102:1368-74.
34. Voutsadakis IA. Peroxisome proliferator-activated receptor-γ (PPARγ) and colorectal carcinogenesis. J Cancer Res Clin Oncol 2007;133:917-28.
35. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARγ by lovastatin and rosiglitazone. Int J Cancer 2006;118:2390-8.
36. Bai YP, Liu YH, Chen J, Song T, You Y, Tang ZY, Li YJ, Zhang GG. Rosiglitazone attenuates NF-κB-dependent ICAM-1 and TNF-α production caused by homocysteine via inhibiting ERK1/2/p38MAPK activation. Biochem Biophys Res Commun 2007;360:20-6.